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Abstract
Objectives To test the efficacy of treatment for unilateral visual
loss detected by preschool vision screening and the extent to
which effectiveness varies with initial severity.
Design Randomised controlled trial of full treatment with
glasses and patching, if required, compared with glasses only or
no treatment. Masked assessment of best corrected acuity after
one year of follow up.
Setting Eight UK eye departments.
Participants 177 children aged 3-5 years with mild to moderate
unilateral impairment of acuity (6/9 to 6/36) detected by
screening.
Results Children in the full and glasses treatment groups had
incrementally better visual acuity at follow up than children
who received no treatment, but the mean treatment effect
between full and no treatment was equivalent to only one line
on a Snellen chart (0.11 log units; 95% confidence interval
0.050 to 0.171; P < 0.0001). The effects of treatment depended
on initial acuity: full treatment showed a substantial effect in the
moderate acuity group (6/36 to 6/18 at recruitment) and no
significant effect in the mild acuity group (6/9 to 6/12 at
recruitment) (P = 0.006 for linear regression interaction term).
For 64 children with moderate acuity loss the treatment effect
was 0.20 log units, equivalent to one to two lines on a Snellen
chart. When all children had received treatment, six months
after the end of the trial, there was no significant difference in
acuity between the groups.
Conclusions Treatment is worth while in children with the
poorest acuity, but in children with mild (6/9 to 6/12) unilateral
acuity loss there was little benefit. Delay in treatment until the
age of 5 did not seem to influence effectiveness.
Introduction
Amblyopia is a form of cerebral visual impairment caused by
abnormal vision, commonly uncorrected refractive error, during a
sensitive period of development.1–4 Treatment is thought to be
effective only during this sensitive period,which varies for different
types of amblyopia but most commonly lasts until 7 years of age.5–7
The most common forms of amblyopia are monocular, due to
squint (strabismic amblyopia), or refractive error, with a prevalence
of 2-4%.8 9 Such impairment is a bar to certain occupations, affects
binocular vision and stereopsis, and causes considerable disability
if the normal eye suffers trauma or disease.10
Strabismic amblyopia usually presents with a visible squint,
but refractive amblyopia or a small angle strabismus may not be
detected until it is too late for treatment to be effective. Preschool
vision screening became widespread in the United Kingdom and
Europe during the 1970s and 1980s, with the aim of detecting
unilateral amblyopia at a stage when treatment would be
effective.11–16 Methods of screening and recommended referral
criteria vary,17 though children are usually referred if acuity is 6/9
or worse.18 Glasses alone may prevent or treat refractive amblyo-
pia,19 but most children require additional treatment with patch-
ing3 or penalisation of the normal eye (by blurring vision, usually
with atropine drops).20 This treatment was developed empirically,
supported by animal studies,1 21 but has never been subjected to
a randomised controlled trial.
Recent studies have raised concerns about the appropriate-
ness of amblyopia as a target condition for early screening22 and
the possible adverse psychological impact of treatment weighed
against the limited disability it causes.23 A systematic review con-
cluded that there was no robust evidence for the effectiveness of
amblyopia treatment.15 Our study arose out of the controversy
generated by that review. We looked at the effectiveness of treat-
ment by patching plus glasses or glasses alone compared with no
treatment and explored the extent to which effectiveness varied
with initial severity.
Methods
The study was a pragmatic, single masked, randomised control-
led trial in eight UK children’s eye clinics. It was designed to
assess the benefits of current standard treatment of children
who fail preschool vision screening tests.
Recruitment of participants
In all centres preschool vision testing was already conducted by
community based orthoptists. Children were referred to
dedicated recruitment clinics if, after two standard screening
tests, they had 6/6 vision in one eye and 6/9 to 6/36 vision in the
other. If the acuity findings were confirmed in the recruitment
clinic, the child was eligible to join the trial. Consent was then
requested from the carer by the trial centre ophthalmologist. If
the ophthalmologist found any other ocular abnormalities the
child was excluded from the trial. A training video of the recruit-
ment procedure and trial protocol handbooks were supplied to
all participating centres. At each research review an assessment
form was completed and forwarded to the trial office.
Allocation to treatment
Once consent was obtained, the child was randomly allocated to a
treatment group by the researchers phoning the trial centre,where
allocation tickets, computer generated for each centre before the
start of recruitment, were stored in numbered, sealed, opaque
envelopes. The computer program produced random permuted
block allocation with random swapping between blocks of length 4
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and 6. Randomisation was stratified by trial centre and acuity for
entry acuity of 6/9, 6/12 and 6/18, but children with acuity 6/24
and 6/36 were randomised together across all centres.
Treatment
After randomisation, all children were tested for refractive error
with cycloplegic drops to eliminate artefact due to accommoda-
tion.Glasses were dispensed to children only in the full and glasses
groups, who were then seen after six weeks to verify the glasses
prescription. Children in the full treatment group then started to
wear a patch if their corrected acuity remained reduced. They were
reviewed every six weeks andmanaged by the treatment orthoptist
according to protocol. Children in the glasses group received no
further treatment for 52 weeks. Children in the control group (no
treatment) received no active treatment for 52 weeks. For those
children receiving treatment, we assessed compliance using weekly
parental diaries for the first 12 weeks of glasses wear and with daily
diaries for the duration of patching treatment.
Measurements
A research orthoptist, who remained masked throughout to the
child’s treatment group, assessed vision at 24, 52, 54, and 78
weeks. If masking was breached, subsequent testing was
performed by a deputy research orthoptist. At six months, if a
child in the no treatment and glasses treatment groups
developed manifest squint or acuity below 6/36 they were
offered full treatment. As children in the no treatment group did
not receive glasses until after the 52 week follow up, visual acuity
testing was performed without glasses for all groups at 24 and 52
weeks. At the 52 week follow up children in all groups were pre-
scribed glasses. Children in the no treatment group were
instructed to begin wearing glasses only the day before the 54
week follow up, when best corrected (that is, without glasses)
visual acuity was recorded.
Children in the no treatment and glasses treatment groups
were then offered patching treatment as required with the same
protocol. Six months later, 18 months after recruitment, we saw
all the children once more and tested their best corrected visual
acuity.
Analysis
Prestated outcome measures were uncorrected and corrected
logMAR acuity, compared between the three groups at 52 and
54 week follow up. A planned subgroup analysis compared chil-
dren whose acuity loss at recruitment was mild (6/12 to 6/9)
with those whose acuity loss was moderate (6/36 to 6/18). Log-
MAR acuity was obtained with Glasgow acuity cards24 (marketed
as LogMAR Crowded Test by Keeler, Windsor) and were used in
preference to Snellen acuity values as logMAR is a continuous
measure of acuity, more suited to statistical analysis. Change in
acuity from recruitment was a secondary outcome measure for
those able to perform logMAR testing at recruitment. Analysis
was by intention to treat, with all children for whom follow up
data were available analysed in their allocated groups. The main
planned analytical method was trend in analysis of variance
between treatment groups with linear regression used to fit the
interaction term for the initial acuity group.
All acuities shown in this paper are crowded logMAR, and,
unless otherwise stated, all follow up acuity data are best
corrected acuity. Prior power calculations were limited by a lack
of data but indicated that 50 children in each group would sup-
ply ample power to detect a clinically useful difference of one or
more lines on a Snellen chart.
Results
Recruitment to the trial opened in April 1999 and closed in
December 2000; 12 month follow up closed in December 2001
and 18 month follow up in June 2002. Of 490 children in eight
trial centres thought to fulfil trial entry criteria at screening, 434
were seen at recruitment clinics, but 180 of these no longer met
the trial entry criteria (of these, 113 had normal vision, 53 had
reduced acuity in both eyes (fig 1). The parents of 77 children
refused to participate, with higher rates of refusal among parents
Registered patients (n=490) Excluded (n=56, 11%) (eligibility not known)
  Lost to routine clinic (n=11)
  Refused at screen (n=14)
  Failed to attend recruitment clinic (n=31)
Assessed (n=434)
Randomised (n=177)
No treatment (n=59)
  Did not receive
  intervention: 4 rejected
  allocation immediately, 1
  rejected treatment at 24 weeks;
  full treatment then given
Glasses only (n=59)
  Did not receive intervention
  (no refractive error, n=3)
Full treatment (glasses with or
without patch) (n=59)
  Did not receive intervention
  (insufficient acuity loss, n=1;
  non-compliance, n=3)
Excluded (n=257)
  Not meeting inclusion criteria (n=180)
  Refused to participate (n=77)
Lost to follow up:
  52 weeks (n=3)
  54 weeks (n=4)
  78 weeks (n=9)
  Reason: failed to attend
Lost to follow up:
  52 weeks (n=3)
  54 weeks (n=4)
  78 weeks (n=8)
  Reason: failed to attend
Lost to follow up:
  52 weeks (n=3)
  54 weeks (n=5)
  78 weeks (n=6)
  (4 failed to attend, 2 moved)
Analysed:
  Uncorrected acuity at 52 weeks
  (n=56),
  Corrected acuity at 54 weeks
  (n=55), at 78 weeks (n=50)
Analysed:
  Uncorrected acuity at 52 weeks
  (n=56),
  Corrected acuity at 54 weeks
  (n=55), at 78 weeks (n=51)
Analysed:
  Uncorrected acuity at 52 weeks
  (n=56),
  Corrected acuity at 54 weeks
  (n=54), at 78 weeks (n=53)
Fig 1 Participant flow through trial of treatment of visual impairment detected at preschool vision screening
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of children with lower acuity. There were thus 177 children who
joined the study at a mean age of 48.1 (SD 5.0) months (table 1)
having been screened at a mean age of 45.6 (4.6) months. Sixty
seven (38%) children were in the moderate category. The median
number of recruits per centre was 21.5 (range 5-52). The
randomisation allocated 59 children to each group, with a
reasonable distribution of acuity (table 2). Of the total, 173 (98%)
had a significant refractive error, 127 (72%) of whom had
anisometropia (a significant difference in refractive error
between the two eyes) (table 2).
In the first six weeks, 74 (69%) of the 107 children prescribed
glasses wore them most or all of the time, with only six (6%) not
wearing them at all. In the full treatment group, vision in 13 with
mild acuity loss and four with moderate loss improved to normal
with glasses correction alone. The 42 remaining (71%) required
patching for a mean of 20 (SD 10) weeks. Twenty five wore their
patch for two thirds or more of prescribed time, but three would
not wear it at all (fig 1).
Five parents in the no treatment group rejected their
allocation, four immediately and one after six months. The
children then received active treatment; two of these subsequently
defaulted from all follow up. No child required active treatment
because of deterioration.
Follow up data at 52 weeks were available for 168 (95%) chil-
dren and at 54 weeks for 164 (93%) (fig 1). Children in the full
and glasses treatment groups had incrementally better
uncorrected and corrected visual acuity at follow up compared
with those in the no treatment group, but the overall treatment
effect was small (table 3). However, at follow up only two (4%)
children in the full treatment group still had moderate acuity loss
(worse than Snellen equivalent 6/12 (logMAR < 0.3)) compared
with 15 (27%) in the untreated group (2 trend P = 0.001).
Glasses produced a fairly fixed gain of around 0.08 log units at
all acuities, but the treatment effects differed depending on initial
acuity (fig 2, table 4). Full treatment showed a substantial effect in
the moderate acuity group and no significant effect in the mild
acuity group (P = 0.006 for linear regression interaction term).
Change in acuity since recruitment showed similar treatment
effects to those seen between treatment groups at 12month follow
up. The change in acuity for the no treatment group was a mean
gain without glasses of 0.1 (SD 0.2) log units for the mild and 0.05
(SD 0.16) for the moderate initial acuity group. Preplanned analy-
sis by centre showed no differences in the treatment effect after
adjustment for initial acuity, which did differ between centres.
After 54 week follow up, children in the no treatment and
glasses treatment groups received treatment according to the
protocol for the full treatment group (table 5). In the no
treatment group, seven (13%) had normal acuity and received no
treatment. Twenty four (44%) achieved normal acuity with
glasses correction only, and 24 (44%) required patching in addi-
tion to glasses. In the glasses group, 20 (36%) needed treatment
with patching. In addition, seven children in the full group
required retreatment with patching at this point.
At 78 week follow up, six months after the formal end point
of the trial, 154 (87%) children attended and there was no signifi-
cant difference in acuity between the three treatment groups
(tables 3 and 4).
Discussion
Previous studies in humans and animals have claimed that
amblyopia can, with good compliance, be improved with
treatment.20 21 25 26 However, it is not known what level of loss of
acuity merits treatment as no previous study has included an
untreated control group and many have excluded children with
milder acuity loss.We also specifically evaluated the treatability of
children identified by standard screening programmes, which
will inevitably also identify some children who are not truly
amblyopic but who can be identified as such only in retrospect,
after their acuity has returned to normal with glasses.
Avoiding bias
Our trial was designed to minimise possible sources of bias. Allo-
cation to treatment was managed centrally, outcomes were
assessed masked, and different testing methods were used for the
trial to reduce practice effects. It was not feasible to test all children
with the same frequency as those in the full treatment group, so we
cannot rule out the possibility that these children may have
become generally more proficient at vision testing. The analysis
was by intention to treat, which could underestimate the true treat-
ment effect. However, only five parents rejected allocation to no
treatment and compliance was reasonable. The trial was amply
Table 1 Baseline data for all children who were eligible for the trial
Eligible Refused Recruited
No of children 254 77 177
Mean (SD) age at recruitment
(months)
47.7 (4.9) 47.4 (4.3) 48.1 (5.0)
No (%) with Snellen acuity:
6/9 78 (31) 20 (26) 58 (33)
6/12 73 (29) 21 (27) 52 (29)
6/18 54 (21) 12 (16) 42 (24)
6/24 and 6/36 49 (19) 24 (31) 25 (14)
No (%) with microtropia 10 (4) 4 (5) 6 (3)
Table 2 Baseline data at recruitment, by allocated treatment group. Values
are number (%) unless otherwise stated
No treatment Glasses Full Total
No of children 59 59 59 177
Mean (SD) age (months) 48.4 (5.1) 47.1 (5.2) 47.6 (4.5) 47.7 (4.9)
Snellen acuity:
6/9 20 20 18 58 (33)
6/12 15 18 19 52 (29)
6/18 14 14 14 42 (24)
6/24* 7 3 2 12 (7)
6/36* 3 4 6 13 (7)
Microtropia 4 2 0 6 (3)
Anisometropia 45 41 41 127 (72)
*Randomised as one group.
Snellen acuity at recruitment
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Fig 2 Corrected crowded logMAR acuity at 54 weeks by initial Snellen acuity level
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powered to detect a clinically useful treatment effect, so it is
unlikely that important treatment effects have been missed. It
might be argued that the patching treatment regimens used were
insufficiently aggressive, but these are the regimens in routine
clinical use.27 The results of the trial should be generalisable to any
centre treating children with unilateral visual impairment as we
used standard screening criteria, recruited over two thirds of eligi-
ble children, and included a wide range of initial acuity levels.
Although the age range in the trial was narrow, the effect of
deferred treatment in the no treatment group indicates that these
findings are also applicable to children identified at school entry.
Their relevance to amblyopia secondary to squint is less clear.
Responses to treatment
The overall response to treatment was disappointing: an increase
equivalent to one line on a Snellen chart. However, children with
moderate initial acuity improved with full treatment from 6/18
or worse to a mean acuity close to 6/9, while those in the mild
group were essentially unchanged. The benefit to acuity from 12
months of wearing glasses compared with no treatment suggests
that the treatment effect from glasses alone is limited.19 The most
striking effect was the additive effect of patching in the moderate
acuity group.
As in all trials, there is the possibility that those left untreated
may suffer, but the no treatment group in fact showed a tendency
to spontaneous improvement. This is consistent with results from
another study of amblyopia28 but contrasts with the results of an
uncontrolled study, in which patients who did not comply with
treatment deteriorated over time.29 However, it is well known that
non-compliant people are not representative of patients in general
and they tend to have a worse prognosis. Currently, continued
wearing of glasses is recommended until the age of 7, even if acu-
ity improves to normal, to prevent the development of refractive
amblyopia.30 Results in the untreated group, however, suggest that
the risk of subsequently developing amblyopia is slight.
In many districts without preschool screening children are
not detected or treated until school entry, the age at which our
untreated group completed the trial and were offered treatment.
The post-trial follow up shows that deferring their treatment did
not limit their potential for improvement and nearly halved the
proportion of children needing patching at all. This is consistent
with another study that showed that presenting acuity, rather
than age, is the most important determinant of outcome.6 The
late results in the full group also suggest that the treatment
effects persist well after most patching treatment has ceased. The
glasses group with moderate initial acuity, in whom patching
treatment was deferred, showed no overall gain in acuity at post-
trial follow up.While this is probably a random effect, it raises the
question whether prior refractive correction might in some way
limit the effectiveness of subsequent patching.
Conclusions
Amblyopia and refractive error are common worldwide, and
many countries have screening programmes to detect asympto-
matic visual defects in children. Thus the implications of our
findings are considerable and should provide helpful evidence
for future service planning. Children with a moderate acuity loss
of 6/18 or worse showed a clear cut response to treatment, which
Table 3 Visual acuity after follow up to trial end point and six months after trial, by treatment group
LogMAR acuity
No treatment Glasses Full
P value for trend
(ANOVA)
Mean (SD)
logMAR
Mean (SD)
logMAR
Mean difference (95% CI)
from no treatment
Mean (SD)
logMAR
Mean difference (95% CI)
from no treatment
At trial end point
Uncorrected acuity (n=168) 0.424 (0.24) (n=56) 0.381 (0.23) (n=56) 0.043 (−0.05 to 0.13) 0.336 (0.20) (n=56) 0.088 (0.01 to 0.17) 0.041
Best corrected acuity (n=164) 0.301 (0.20) (n=55) 0.216 (0.17) (n=55) 0.085 (0.02 to 0.15) 0.193 (0.12) (n=54) 0.109 (0.05 to 0.17) 0.001
Six months after trial end
Best corrected acuity (n=154) 0.170 (0.15) (n=50) 0.197 (0.16) (n=51) 0.03 (−0.09 to 0.03) 0.170 (0.13) (n=53) 0.0004 (−0.06 to 0.05) 0.996
ANOVA=analysis of variance.
Table 4 Visual acuity after follow up to trial end point and six months after trial, by treatment group and initial acuity
No treatment Glasses Full
P value for trend
(ANOVA)
Mean (SD)
logMAR
Mean (SD)
logMAR
Mean difference (95% CI)
from no treatment
Mean (SD)
logMAR
Mean difference (95% CI)
from no treatment
At end of trial
Mild* acuity loss (n=101) 0.22 (0.17) (n=33) 0.16 (0.14) (n=35) 0.058 (−0.02 to 0.13) 0.18 (0.11) (n=33) 0.045 (−0.02 to 0.11) 0.11
Moderate† acuity loss (n=63) 0.42 (0.19) (n=22) 0.31 (0.17) (n=20) 0.112 (−0.002 to 0.23) 0.22 (0.13) (n=21) 0.203 (0.10 to 0.30) 0.0002
Six months after end of trial
Mild* acuity loss (n=91) 0.13 (0.08) (n=28) 0.13 (0.12) (n=31) 0.00 (−0.06 to 0.05) 0.16 (0.12) (n=32) −0.03 (−0.08 to 0.03) 0.327
Moderate† acuity loss (n=63) 0.22 (0.20) (n=22) 0.30 (0.18) (n=20) −0.08 (−0.19 to 0.04) 0.19 (0.14) (n=21) 0.03 (−0.07 to 0.14) 0.575
*6/9 or 6/12 at presentation. †6/18 to 6/36 at presentation.
Table 5 Change in acuity after one year, by treatment group and initial acuity
Initial acuity category
No treatment Glasses only Full
P value for trend
Mean (SD)
logMAR
Mean (SD)
logMAR
Mean difference (95% CI)
from no treatment
Mean (SD)
logMAR
Mean difference (95% CI)
from no treatment
Change in corrected acuity at 54 week follow up
Mild 0.19 (0.17) (n=30) 0.24 (0.14) (n=31) 0.05 (−0.03 to 0.13) 0.23 (0.17) (n=31) 0.04 (−0.06 to 0.13) 0.38*
Moderate 0.25 (0.21) (n=21) 0.35 (0.20) (n=18) 0.11 (−0.03 to 0.24) 0.52 (0.19) (n=20) 0.27 (0.14 to 0.39) <0.001*
Worse (change >0.1 logMAR) uncorrected acuity at 52 weeks
Mild 13% (4) 6% (2) — 10% (3) — 0.28†
Moderate 24% (5) 11% (2) — 15% (3) — 0.13†
*ANOVA. †2.
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itself arguably justifies screening to identify and treat these
children. In contrast, children with mild acuity loss, who
represent over half those identified with unilateral acuity impair-
ment at screening in this and other studies,31 received little ben-
efit from either treatment. This level of impairment, though
often excluded from studies,20 25 is still commonly treated in rou-
tine clinical practice.We argue that children with 6/9 in only one
eye should no longer constitute screen failures and do not justify
treatment, even with glasses.
Nearly 40% of the children referred for treatment did not in
fact have the target condition. This was despite two tests in the
community and presumably reflects difficulties in testing
preschool children. This, together with the good response seen
in those whose treatment was deferred, supports the use of rela-
tively later screening, as recently suggested.32
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What is already known on this topic
Preschool vision screening aims to detect amblyopia at a
stage when treatment is effective
Amblyopia has conventionally been treated with glasses,
supplemented by patching of the better eye if necessary
Treated children tend to improve over time, but no study
has included an untreated control group or compared
outcomes for different levels of acuity at presentation
What this study adds
Treatment of children with considerably reduced acuity
(6/18 and worse) can result in a mean acuity equivalent to
6/9 on the Snellen chart
Children with 6/9 or 6/12 initial acuity show little benefit
from treatment
Children whose treatment is deferred from age 4 until age
5 have the same acuity after treatment, but fewer need
patching treatment at all
Over a third of children thought to require treatment after
repeat screening do not have acuity loss
Papers
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